EUVIMEDEUVIMED entdecken
Crossref

PDK1 regulates the progression of esophageal squamous cell carcinoma through metabolic reprogramming

Yingchao Ma, Xishen Zhang, Xiao Han, Zhizhong Hao, Rong Ji, Jianhui Li, Wenna Guo, Yanting Zhang, Fangxia Guan, Shanshan Ma iD

Molecular Carcinogenesis · 2023

DOI: 10.1002/mc.23531 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2023. Verfasst von Yingchao Ma und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, MicroRNAs. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Esophageal squamous cell carcinoma (ESCC) is one of the deadliest human malignancies characterized by late‐stage diagnosis, drug resistance, and poor prognosis. Pyruvate dehydrogenase kinase 1 (PDK1) plays an important role in regulating the metabolic reprogramming of cancer cells. However, its expression, function, and regulatory mechanisms of PDK1 in ESCC have not been reported. In this study, we found that PDK1 silence and dichloroacetic acid (DCA) significantly inhibited the growth of ESCC cells and induced cell apoptosis. Interestingly, PDK1 is a direct target of miR‐6516‐5p, and miR‐6516‐5p/PDK1 axis suppressed the growth of ESCC cell by inhibiting glycolysis. Moreover, DCA and cisplatin (cis‐diammine‐dichloroplatinum, DDP) synergistically inhibited the progression and glycolysis ability of ESCC cells both in vitro and in vivo by increasing oxidative stress via the inhibition of the Keap1/Nrf2 signaling pathway. And, Tert‐butylhydroquinone (TBHQ), a specific activator of the Keap1/Nrf2 signaling, could diminish the synergic antitumor effects of DCA and DDP on ESCC cells. Collectively, our findings indicate that PDK1 may regulate the progression of ESCC by metabolic reprogramming, which provides new strategy for the treatment of ESCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal Squamous Cell CarcinomaEsophageal NeoplasmsMicroRNAsHumansKelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2CisplatinCell ProliferationCell Line, TumorGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

cisplatinesophageal squamous carcinoma cellsglycolysismicroRNApyruvate dehydrogenase kinase 1

Substanzen

Kelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2CisplatinMicroRNAs

Autor:innen und Institutionen

  • School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China.
  • Department of Pathology, Xuchang Central Hospital Affiliated to Henan University of Science and Technology, Xuchang, Henan, China.

ORCID-Profile: Shanshan Ma

Zitieren

APA

Ma, Y., Zhang, X., Han, X., Hao, Z., Ji, R., Li, J., Guo, W., Zhang, Y., Guan, F., & Ma, S. (2023). PDK1 regulates the progression of esophageal squamous cell carcinoma through metabolic reprogramming. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23531

Vancouver

Ma Y, Zhang X, Han X, Hao Z, Ji R, Li J, et al. PDK1 regulates the progression of esophageal squamous cell carcinoma through metabolic reprogramming. Molecular Carcinogenesis. 2023. doi:10.1002/mc.23531

BibTeX
@article{Ma2023,
  author = {Ma, Yingchao and Zhang, Xishen and Han, Xiao and Hao, Zhizhong and Ji, Rong and Li, Jianhui and Guo, Wenna and Zhang, Yanting and Guan, Fangxia and Ma, Shanshan},
  title = {PDK1 regulates the progression of esophageal squamous cell carcinoma through metabolic reprogramming},
  journal = {Molecular Carcinogenesis},
  year = {2023},
  doi = {10.1002/mc.23531}
}
Kostenlos starten →